RGD Reference Report - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors: Huang, Chaolin  Wang, Yeming  Li, Xingwang  Ren, Lili  Zhao, Jianping  Hu, Yi  Zhang, Li  Fan, Guohui  Xu, Jiuyang  Gu, Xiaoying  Cheng, Zhenshun  Yu, Ting  Xia, Jiaan  Wei, Yuan  Wu, Wenjuan  Xie, Xuelei  Yin, Wen  Li, Hui  Liu, Min  Xiao, Yan  Gao, Hong  Guo, Li  Xie, Jungang  Wang, Guangfa  Jiang, Rongmeng  Gao, Zhancheng  Jin, Qi  Wang, Jianwei  Cao, Bin 
Citation: Huang C, etal., Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
RGD ID: 30309212
Pubmed: PMID:31986264   (View Abstract at PubMed)
PMCID: PMC7159299   (View Article at PubMed Central)
DOI: DOI:10.1016/S0140-6736(20)30183-5   (Journal Full-text)


BACKGROUND: A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.
METHODS: All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.
FINDINGS: By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0-58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0-13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα.
INTERPRETATION: The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies.
FUNDING: Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CCL2HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CCL3HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CCL4HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CSF2HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CSF3HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CXCL10HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
CXCL8HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
Ccl2RatCOVID-19 severityISOCCL2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Ccl2MouseCOVID-19 severityISOCCL2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Ccl3RatCOVID-19 severityISOCCL3 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Ccl3MouseCOVID-19 severityISOCCL3 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Ccl4RatCOVID-19 severityISOCCL4 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Ccl4MouseCOVID-19 severityISOCCL4 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Csf2RatCOVID-19 severityISOCSF2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Csf2MouseCOVID-19 severityISOCSF2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Csf3RatCOVID-19 severityISOCSF3 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Csf3MouseCOVID-19 severityISOCSF3 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Cxcl10RatCOVID-19 severityISOCXCL10 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Cxcl10MouseCOVID-19 severityISOCXCL10 (Homo sapiens)protein:increased expression:plasma (human)RGD 
FGF2HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
Fgf2RatCOVID-19 severityISOFGF2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Fgf2MouseCOVID-19 severityISOFGF2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
IFNGHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL10HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL13HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL17AHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL1BHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL1R1HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL2HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL4HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL6HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL7HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IL9HumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
IfngRatCOVID-19 severityISOIFNG (Homo sapiens)protein:increased expression:plasma (human)RGD 
IfngMouseCOVID-19 severityISOIFNG (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il10RatCOVID-19 severityISOIL10 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il10MouseCOVID-19 severityISOIL10 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il13RatCOVID-19 severityISOIL13 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il13MouseCOVID-19 severityISOIL13 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il17aRatCOVID-19 severityISOIL17A (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il17aMouseCOVID-19 severityISOIL17A (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il1bRatCOVID-19 severityISOIL1B (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il1bMouseCOVID-19 severityISOIL1B (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il1r1RatCOVID-19 severityISOIL1R1 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il1r1MouseCOVID-19 severityISOIL1R1 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il2RatCOVID-19 severityISOIL2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il2MouseCOVID-19 severityISOIL2 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il4RatCOVID-19 severityISOIL4 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il4MouseCOVID-19 severityISOIL4 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il6RatCOVID-19 severityISOIL6 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il6MouseCOVID-19 severityISOIL6 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il7RatCOVID-19 severityISOIL7 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il7MouseCOVID-19 severityISOIL7 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il9RatCOVID-19 severityISOIL9 (Homo sapiens)protein:increased expression:plasma (human)RGD 
Il9MouseCOVID-19 severityISOIL9 (Homo sapiens)protein:increased expression:plasma (human)RGD 
PDGFBHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
PdgfbRatCOVID-19 severityISOPDGFB (Homo sapiens)protein:increased expression:plasma (human)RGD 
PdgfbMouseCOVID-19 severityISOPDGFB (Homo sapiens)protein:increased expression:plasma (human)RGD 
TNFHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
TnfRatCOVID-19 severityISOTNF (Homo sapiens)protein:increased expression:plasma (human)RGD 
TnfMouseCOVID-19 severityISOTNF (Homo sapiens)protein:increased expression:plasma (human)RGD 
VEGFAHumanCOVID-19 severityIEP protein:increased expression:plasma (human)RGD 
VegfaRatCOVID-19 severityISOVEGFA (Homo sapiens)protein:increased expression:plasma (human)RGD 
VegfaMouseCOVID-19 severityISOVEGFA (Homo sapiens)protein:increased expression:plasma (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ccl2  (C-C motif chemokine ligand 2)
Ccl3  (C-C motif chemokine ligand 3)
Ccl4  (C-C motif chemokine ligand 4)
Csf2  (colony stimulating factor 2)
Csf3  (colony stimulating factor 3)
Cxcl10  (C-X-C motif chemokine ligand 10)
Fgf2  (fibroblast growth factor 2)
Ifng  (interferon gamma)
Il10  (interleukin 10)
Il13  (interleukin 13)
Il17a  (interleukin 17A)
Il1b  (interleukin 1 beta)
Il1r1  (interleukin 1 receptor type 1)
Il2  (interleukin 2)
Il4  (interleukin 4)
Il6  (interleukin 6)
Il7  (interleukin 7)
Il9  (interleukin 9)
Pdgfb  (platelet derived growth factor subunit B)
Tnf  (tumor necrosis factor)
Vegfa  (vascular endothelial growth factor A)

Genes (Mus musculus)
Ccl2  (C-C motif chemokine ligand 2)
Ccl3  (C-C motif chemokine ligand 3)
Ccl4  (C-C motif chemokine ligand 4)
Csf2  (colony stimulating factor 2 (granulocyte-macrophage))
Csf3  (colony stimulating factor 3 (granulocyte))
Cxcl10  (C-X-C motif chemokine ligand 10)
Fgf2  (fibroblast growth factor 2)
Ifng  (interferon gamma)
Il10  (interleukin 10)
Il13  (interleukin 13)
Il17a  (interleukin 17A)
Il1b  (interleukin 1 beta)
Il1r1  (interleukin 1 receptor, type I)
Il2  (interleukin 2)
Il4  (interleukin 4)
Il6  (interleukin 6)
Il7  (interleukin 7)
Il9  (interleukin 9)
Pdgfb  (platelet derived growth factor, B polypeptide)
Tnf  (tumor necrosis factor)
Vegfa  (vascular endothelial growth factor A)

Genes (Homo sapiens)
CCL2  (C-C motif chemokine ligand 2)
CCL3  (C-C motif chemokine ligand 3)
CCL4  (C-C motif chemokine ligand 4)
CSF2  (colony stimulating factor 2)
CSF3  (colony stimulating factor 3)
CXCL10  (C-X-C motif chemokine ligand 10)
CXCL8  (C-X-C motif chemokine ligand 8)
FGF2  (fibroblast growth factor 2)
IFNG  (interferon gamma)
IL10  (interleukin 10)
IL13  (interleukin 13)
IL17A  (interleukin 17A)
IL1B  (interleukin 1 beta)
IL1R1  (interleukin 1 receptor type 1)
IL2  (interleukin 2)
IL4  (interleukin 4)
IL6  (interleukin 6)
IL7  (interleukin 7)
IL9  (interleukin 9)
PDGFB  (platelet derived growth factor subunit B)
TNF  (tumor necrosis factor)
VEGFA  (vascular endothelial growth factor A)


Additional Information